These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 15531493)

  • 1. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C; Harnett M; Dobs AS; Swerdloff RS
    J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men.
    Qoubaitary A; Meriggiola C; Ng CM; Lumbreras L; Cerpolini S; Pelusi G; Christensen PD; Hull L; Swerdloff RS; Wang C
    J Androl; 2006; 27(6):853-67. PubMed ID: 16837736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
    Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M; Nieschlag E
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which testosterone replacement therapy?
    Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
    Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
    Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Ernst M
    Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
    Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
    Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth.
    Butler GE; Sellar RE; Walker RF; Hendry M; Kelnar CJ; Wu FC
    J Clin Endocrinol Metab; 1992 Jul; 75(1):37-44. PubMed ID: 1619029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate.
    Partsch CJ; Weinbauer GF; Fang R; Nieschlag E
    Eur J Endocrinol; 1995 Apr; 132(4):514-9. PubMed ID: 7711892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of various modes of androgen substitution therapy on erythropoiesis.
    Jockenhövel F; Vogel E; Reinhardt W; Reinwein D
    Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
    Behre HM; Abshagen K; Oettel M; Hübler D; Nieschlag E
    Eur J Endocrinol; 1999 May; 140(5):414-9. PubMed ID: 10229906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.